OLD National Bancorp IN decreased its position in shares of GSK plc (NYSE:GSK – Free Report) by 5.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,002 shares of the pharmaceutical company’s stock after selling 584 shares during the quarter. OLD National Bancorp IN’s holdings in GSK were worth $356,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Northwest Investment Counselors LLC boosted its stake in GSK by 339.0% during the 4th quarter. Northwest Investment Counselors LLC now owns 777 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 600 shares during the last quarter. Janiczek Wealth Management LLC boosted its stake in GSK by 49.8% during the 4th quarter. Janiczek Wealth Management LLC now owns 915 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 304 shares during the last quarter. Glassman Wealth Services boosted its stake in GSK by 504.6% during the 4th quarter. Glassman Wealth Services now owns 925 shares of the pharmaceutical company’s stock worth $33,000 after acquiring an additional 772 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in GSK by 61.3% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock worth $42,000 after acquiring an additional 368 shares during the last quarter. Finally, Concord Wealth Partners bought a new position in GSK during the 4th quarter worth approximately $45,000. Institutional investors own 13.29% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on GSK shares. StockNews.com initiated coverage on shares of GSK in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. Deutsche Bank Aktiengesellschaft raised shares of GSK from a “hold” rating to a “buy” rating in a research note on Friday, March 17th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $1,576.88.
GSK Price Performance
GSK (NYSE:GSK – Free Report) last issued its earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The business had revenue of $8.45 billion for the quarter, compared to the consensus estimate of $8.55 billion. GSK had a net margin of 47.85% and a return on equity of 43.27%. On average, research analysts forecast that GSK plc will post 3.66 earnings per share for the current fiscal year.
GSK Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, July 13th. Investors of record on Friday, May 19th will be issued a dividend of $0.3475 per share. This represents a $1.39 dividend on an annualized basis and a yield of 3.94%. This is an increase from GSK’s previous quarterly dividend of $0.34. The ex-dividend date of this dividend is Thursday, May 18th. GSK’s payout ratio is presently 16.43%.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Stories
- Five stocks we like better than GSK
- Tesla Production Cranks Into High Gear, Shares Follow
- Ford Soars 30% YTD After Breaking Out: What’s Next?
- Acuity Brands Lights Up Opportunity In The Industrial Sector
- Overstock Looks Beyond Overbought After Bed Bath Re-Brand
- Tecnoglass Shines Bright As Analysts Bullish On Growth Potential
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Free Report).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
